Benjamin Halladay - 16 Nov 2022 Form 3 Insider Report for Esperion Therapeutics, Inc. (ESPR)

Role
Chief Financial Officer
Signature
/s/ Benjamin Looker, by power of attorney
Issuer symbol
ESPR
Transactions as of
16 Nov 2022
Net transactions value
$0
Form type
3
Filing time
16 Nov 2022, 15:11:23 UTC
Next filing
12 Dec 2022
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
holding ESPR Common Stock 19,771 16 Nov 2022 Direct F1, F2, F3, F4, F5
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Includes an award of restricted stock units ("RSUs"), of which 152 RSUs are currently unvested. Such award vests over a four (4) year period as follows: 25% vested on January 20, 2021 and the remainder vests in equal quarterly installments over the three (3) year period thereafter, subject to continued service.
F2 Includes an award of RSUs, of which 312 RSUs are currently unvested. Such award vests over a four (4) year period in equal quarterly installments, the first of which vested on May 15, 2021, subject to continued service.
F3 Includes an award of RSUs, of which 309 RSUs are currently unvested. Such award vests over a four (4) year period in equal quarterly installments, the first of which vested on October 15, 2021, subject to continued service.
F4 Includes an award of RSUs, of which 5,470 RSUs are currently unvested. Such award vests over a four (4) year period in equal quarterly installments, the first of which vested on June 15, 2022, subject to continued service.
F5 Includes an award of RSUs, of which 7,800 RSUs are currently unvested. Such award will vest as follows: 50% shall vest upon CVOT public presentation of results; and 50% shall vest upon obtaining approval for cardiovascular risk reduction into the U.S. label, subject to continued service.

Remarks:

Exhibit 24 - Power of Attorney